Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Pfizer (NY: PFE)
33.42 USD  -0.51 (-1.50%)
Streaming Delayed Price  /  Updated: 4:19 AM EST, Feb 26, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,993
Open 33.93
Bid (Size) 33.60 (15)
Ask (Size) 33.65 (5)
Prev. Close 33.93
Today's Range 33.42 - 33.93
52wk Range 33.71 - 44.56
Shares Outstanding 5,849,571,048
Dividend Yield 4.07%
Performance
YTD
-14.61%
-14.61%
1 Month
-16.78%
-16.78%
3 Month
-12.74%
-12.74%
6 Month
-2.68%
-2.68%
1 Year
-22.42%
-22.42%
Top News
More News
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the Cowen and Company 40th... Read More
from Business Wire News Releases
European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved VYNDAQEL® (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin... Read More
from Business Wire News Releases
More News
Read More
Is the New Pfizer an Attractive Investment?
category Healthcare , Stocks / Equities
from Blogs - TalkMarkets
UPDATE 2-Esperion says cholesterol drug gets U.S. approval; eyes $10 per pill pricing
category companyNews
from Reuters: Company News
The Most Important Stock to Own Over the Next Decade
category Market News , PFE , GOOGL , and 3 more.
from Motley Fool
Pfizer Inc (PFE) Approaches New Upside Target of $35.80
from Comtex SmarTrend® News Briefs
UPDATE 1-Esperion's cholesterol drug gets U.S. approval; to be priced at $10 per pill
category companyNews
from Reuters: Company News
Better Buy: GlaxoSmithKline vs. Eli Lilly
category LLY , INCY , Market News , and 3 more.
from Motley Fool
Is Gilead Sciences Stock a Buy?
category GLPG , Market News , PFE , and 2 more.
from Motley Fool
UPDATE 1-Companies in pharmaceutical supply chain develop system to track counterfeit drugs
category companyNews
from Reuters: Company News
Pharmaceutical companies develop system to better track counterfeit drugs
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.